Stock data
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL) reported revenue of US$0.04M and net income of -US$274.45M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$0.04M | — | -US$269.40M | -US$274.45M | — |
| 2024 | US$0.06M | — | -US$358.75M | -US$342.99M | — |
| 2023 | US$0.13M | — | -US$247.01M | -US$234.63M | — |
| 2022 | US$84.68M | — | -US$187.06M | -US$183.12M | — |
| 2021 | US$10.65M | — | -US$214.78M | -US$250.22M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.00M | -US$44.76M | — |
| 2026-03-31 | US$0.00M | -US$24.15M | — |
| 2025-12-31 | US$0.01M | -US$140.72M | — |
| 2025-09-30 | US$0.01M | -US$38.85M | — |
| 2025-06-30 | US$0.01M | -US$42.68M | — |
| 2025-03-31 | US$0.01M | -US$52.20M | — |
| 2024-12-31 | US$0.01M | -US$191.94M | — |
| 2024-09-30 | US$0.03M | -US$44.58M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.